Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
SEATTLE, Sept. 18, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...